Compumedics Delivers Record FY26 Revenue as SaaS Growth Accelerates

Compumedics shows strong revenue growth, but profit and cash flow remain unproven.

What the company is saying

Compumedics is positioning itself as a growth story, emphasizing record revenue and robust sales orders for FY26. The company wants investors to focus on its 18% year-on-year revenue increase to $60.3 million and the surge in SaaS recurring revenue, which it claims grew approximately 70%. Management highlights the rebound in MEG capital equipment revenue, which contributed $9.7 million after a year of zero revenue in that segment, and points to a 58% increase in segment sales orders to $10.6 million. The announcement frames these achievements as evidence of strong demand across its sleep, neurology, MEG, and connected platform businesses. Forward-looking statements are prominent, with management projecting further double-digit revenue growth and EBITDA growth outpacing revenue in FY27, supported by order book conversion, ongoing MEG activity, SaaS expansion, and a planned US release for Somfit D. However, the company buries the fact that actual FY26 revenue fell short of its April guidance range of $62m to $65m, attributing the miss to external timing factors like helium supply disruptions linked to Middle East conflict, without quantifying the impact. The tone is upbeat and confident, with management using assertive language around growth and future targets, but offering little detail on profitability or cash generation. Notably, non-executive director Christopher Barys resigned after nine months, but the announcement does not elaborate on the reasons or implications. This narrative fits a classic growth-company investor relations strategy: spotlighting top-line momentum and recurring revenue, while downplaying shortfalls and omitting bottom-line details.

What the data suggests

The disclosed numbers confirm that Compumedics achieved record shipped and invoiced revenue of approximately $60.3 million for FY26, an 18% increase over the previous year. Sales orders for FY26 reached $62.7 million, indicating continued demand and a healthy pipeline. SaaS recurring revenue for Somfit and Nexus 360 grew by about 70%, with actual SaaS revenue rising from $4.3 million in FY24 to $6 million in FY25 and $10.2 million in FY26, showing accelerating adoption of the company’s software platforms. MEG capital equipment revenue rebounded sharply, contributing $9.7 million in FY26 after no revenue in FY25, suggesting a recovery or new wins in that segment. Segment sales orders also increased 58% year-on-year to $10.6 million, reinforcing the narrative of broad-based growth. However, the company’s actual revenue came in below its own April guidance of $62m–$65m, a shortfall that is acknowledged but not quantified in terms of impact or duration. Critically, there is no disclosure of net profit, actual EBITDA, cash flow, or balance sheet strength, making it impossible to assess whether revenue growth is translating into sustainable profitability or liquidity. The financial disclosures are detailed for revenue and segment growth, but incomplete for costs, margins, and cash metrics. An independent analyst would conclude that while top-line momentum is real and accelerating, the lack of bottom-line data is a significant gap that tempers the investment case.

Analysis

The announcement presents a positive tone, highlighting record revenue, strong sales orders, and significant SaaS growth, all of which are supported by disclosed numerical data. However, the company does not provide any actual profitability metrics such as net income, EBITDA (only an expectation, not a realised figure), or cash flow, which prevents a full assessment of whether revenue growth is translating into sustainable value. The forward-looking statements about EBITDA growth and future double-digit revenue growth are aspirational and not yet realised, but they are not excessive relative to the evidence of recent revenue momentum. The gap between narrative and evidence is moderate: while the operational growth is real, the lack of profit disclosure and the focus on targets for FY27 introduce some inflation. There is no indication of a large capital outlay with long-dated returns, and most benefits are expected in the near term. The language is upbeat but not extreme, and most claims are grounded in recent performance.

Risk flags

• ●Profitability opacity: The company discloses no net profit, actual EBITDA, or cash flow figures, making it impossible to assess whether revenue growth is translating into sustainable earnings. This matters because top-line growth alone does not guarantee shareholder value if costs are rising or margins are thin.
• ●Guidance miss: FY26 shipped and invoiced revenue came in below the April guidance range of $62m–$65m, despite being a record. The shortfall is attributed to external timing factors, but the lack of quantification or mitigation plan raises questions about forecasting reliability and operational control.
• ●Heavy reliance on forward-looking statements: A significant portion of the announcement is devoted to targets for FY27 and beyond, including double-digit revenue and EBITDA growth. These are not yet realized and depend on continued execution, making the investment case partly speculative.
• ●Segment concentration risk: MEG capital equipment revenue rebounded to $9.7m after a year of zero, but this segment appears volatile and subject to external supply chain disruptions (e.g., helium availability linked to geopolitical conflict). Investors face risk if this revenue stream proves lumpy or unreliable.
• ●Incomplete financial disclosure: The absence of cost, margin, and balance sheet data prevents a full assessment of financial health. Without information on debt, cash reserves, or working capital, investors cannot gauge liquidity or solvency risk.
• ●Execution risk on US Somfit D launch: The company highlights the planned US release of Somfit D as a future growth driver but provides no timeline or regulatory update. Delays or setbacks in this launch could undermine future growth projections.
• ●Board turnover: The resignation of non-executive director Christopher Barys after only nine months may signal governance or strategic disagreements, though the announcement provides no detail. Board instability can be a red flag for investors, especially if not transparently addressed.
• ●Revenue quality risk: While SaaS recurring revenue growth is impressive at 70%, the announcement does not clarify the base, customer retention, or profitability of this segment. High growth from a small or unprofitable base may not be sustainable.

Bottom line

For investors, this announcement confirms that Compumedics is delivering strong revenue and sales order growth, particularly in its SaaS and MEG segments. The company’s top-line momentum is real, with an 18% revenue increase and a 70% jump in recurring SaaS revenue, but the absence of any profit, EBITDA, or cash flow disclosure is a major limitation. The narrative is credible on operational growth but incomplete on financial sustainability, as there is no evidence that higher revenue is translating into actual earnings or cash generation. The resignation of a non-executive director after a short tenure is noted but unexplained, adding a layer of governance uncertainty. To materially improve the investment case, Compumedics would need to disclose actual EBITDA, net profit, and cash flow figures, as well as provide more detail on costs, margins, and the status of key product launches like Somfit D in the US. In the next reporting period, investors should watch for realized profitability, cash metrics, and concrete progress on US regulatory milestones. At present, the signal is worth monitoring but not acting on, unless further disclosures confirm that revenue growth is sustainable and profitable. The single most important takeaway is that while Compumedics is growing fast, the lack of bottom-line transparency means investors are being asked to take the company’s profitability on trust.

Announcement summary

(ASX: CMP) Compumedics has delivered record shipped and invoiced revenue of approximately $60.3 million for FY26, representing an 18% increase on the previous year. The company recorded FY26 sales orders of approximately $62.7m, reflecting continued demand across its sleep, neurology, magnetoencephalography (MEG), and connected platform businesses. Growth in Somfit and Nexus 360 software-as-a-service (SaaS) recurring revenue reached approximately 70%. The group’s MEG capital equipment revenue contributed $9.7m in FY26 after recording no revenue in the segment in FY25, while Somfit and Nexus 360 SaaS revenue increased to $10.2m in FY26 from $6m in FY25 and $4.3m in FY24. Sales orders for the segment increased 58% year-on-year to $10.6m. Compumedics expects FY26 EBITDA to increase on the back of higher revenue, cost discipline, and recurring platform growth. The company enters FY27 targeting further double-digit revenue growth and EBITDA growth at a faster rate than revenue.

Disagree with this article?